251 related articles for article (PubMed ID: 17939102)
21. Hydroalcoholic plant extracts with anti-inflammatory activity.
Herold A; Cremer L; Călugaru A; Tamaş V; Ionescu F; Manea S; Szegli G
Roum Arch Microbiol Immunol; 2003; 62(1-2):117-29. PubMed ID: 15493372
[TBL] [Abstract][Full Text] [Related]
22. Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening.
Franke L; Schwarz O; Müller-Kuhrt L; Hoernig C; Fischer L; George S; Tanrikulu Y; Schneider P; Werz O; Steinhilber D; Schneider G
J Med Chem; 2007 May; 50(11):2640-6. PubMed ID: 17461565
[TBL] [Abstract][Full Text] [Related]
23. Eugenol--the active principle from cloves inhibits 5-lipoxygenase activity and leukotriene-C4 in human PMNL cells.
Raghavenra H; Diwakr BT; Lokesh BR; Naidu KA
Prostaglandins Leukot Essent Fatty Acids; 2006 Jan; 74(1):23-7. PubMed ID: 16216483
[TBL] [Abstract][Full Text] [Related]
24. Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13,610.
Fischer L; Steinhilber D; Werz O
Br J Pharmacol; 2004 Jul; 142(5):861-8. PubMed ID: 15197110
[TBL] [Abstract][Full Text] [Related]
25. Molecular characterization of EP6--a novel imidazo[1,2-a]pyridine based direct 5-lipoxygenase inhibitor.
Wisniewska JM; Rödl CB; Kahnt AS; Buscató El; Ulrich S; Tanrikulu Y; Achenbach J; Rörsch F; Grösch S; Schneider G; Cinatl J; Proschak E; Steinhilber D; Hofmann B
Biochem Pharmacol; 2012 Jan; 83(2):228-40. PubMed ID: 22027220
[TBL] [Abstract][Full Text] [Related]
26. The 5-lipoxygenase inhibitor RF-22c potently suppresses leukotriene biosynthesis in cellulo and blocks bronchoconstriction and inflammation in vivo.
Schaible AM; Filosa R; Krauth V; Temml V; Pace S; Garscha U; Liening S; Weinigel C; Rummler S; Schieferdecker S; Nett M; Peduto A; Collarile S; Scuotto M; Roviezzo F; Spaziano G; de Rosa M; Stuppner H; Schuster D; D'Agostino B; Werz O
Biochem Pharmacol; 2016 Jul; 112():60-71. PubMed ID: 27157409
[TBL] [Abstract][Full Text] [Related]
27. Lipoxygenase inhibitors as potential cancer chemopreventives.
Steele VE; Holmes CA; Hawk ET; Kopelovich L; Lubet RA; Crowell JA; Sigman CC; Kelloff GJ
Cancer Epidemiol Biomarkers Prev; 1999 May; 8(5):467-83. PubMed ID: 10350444
[TBL] [Abstract][Full Text] [Related]
28. Leukotriene modifiers in the treatment of cardiovascular diseases.
Riccioni G; Capra V; D'Orazio N; Bucciarelli T; Bazzano LA
J Leukoc Biol; 2008 Dec; 84(6):1374-8. PubMed ID: 18794213
[TBL] [Abstract][Full Text] [Related]
29. Celecoxib inhibits 5-lipoxygenase.
Maier TJ; Tausch L; Hoernig M; Coste O; Schmidt R; Angioni C; Metzner J; Groesch S; Pergola C; Steinhilber D; Werz O; Geisslinger G
Biochem Pharmacol; 2008 Oct; 76(7):862-72. PubMed ID: 18692027
[TBL] [Abstract][Full Text] [Related]
30. [Inhibition of the arachidonic acid cascade by aza-2-aryl-1,4-naphthoquinone derivatives].
Richwien A; Wurm G
Pharmazie; 2004 Dec; 59(12):906-12. PubMed ID: 15638076
[TBL] [Abstract][Full Text] [Related]
31. Concentration-dependent potentiating and inhibitory effects of Boswellia extracts on 5-lipoxygenase product formation in stimulated PMNL.
Safayhi H; Boden SE; Schweizer S; Ammon HP
Planta Med; 2000 Mar; 66(2):110-3. PubMed ID: 10763581
[TBL] [Abstract][Full Text] [Related]
32. Oxymetazoline inhibits proinflammatory reactions: effect on arachidonic acid-derived metabolites.
Beck-Speier I; Dayal N; Karg E; Maier KL; Schumann G; Semmler M; Koelsch SM
J Pharmacol Exp Ther; 2006 Feb; 316(2):843-51. PubMed ID: 16221739
[TBL] [Abstract][Full Text] [Related]
33. Protein kinase A inhibits leukotriene synthesis by phosphorylation of 5-lipoxygenase on serine 523.
Luo M; Jones SM; Phare SM; Coffey MJ; Peters-Golden M; Brock TG
J Biol Chem; 2004 Oct; 279(40):41512-20. PubMed ID: 15280375
[TBL] [Abstract][Full Text] [Related]
34. Naturally derived anti-HIV agents.
Asres K; Seyoum A; Veeresham C; Bucar F; Gibbons S
Phytother Res; 2005 Jul; 19(7):557-81. PubMed ID: 16161055
[TBL] [Abstract][Full Text] [Related]
35. [Lipoxygenase inhibition and protection of cardiovascular system].
Hisaki R; Fujita H; Saito F; Kanmatsuse K
Nihon Rinsho; 2004 Jan; 62(1):187-92. PubMed ID: 14737852
[TBL] [Abstract][Full Text] [Related]
36. 5-Lipoxygenase-derived lipid mediators are not required for the development of NSAID-induced inflammatory bowel disease in IL-10-/- mice.
Narushima S; DiMeo D; Tian J; Zhang J; Liu D; Berg DJ
Am J Physiol Gastrointest Liver Physiol; 2008 Feb; 294(2):G477-88. PubMed ID: 18048478
[TBL] [Abstract][Full Text] [Related]
37. Development of a fluorescence-based enzyme assay of human 5-lipoxygenase.
Pufahl RA; Kasten TP; Hills R; Gierse JK; Reitz BA; Weinberg RA; Masferrer JL
Anal Biochem; 2007 May; 364(2):204-12. PubMed ID: 17376394
[TBL] [Abstract][Full Text] [Related]
38. Lipoxygenase and prostaglandin G/H synthase cascades in cardiovascular disease.
Zhao L; Grosser T; Fries S; Kadakia L; Wang H; Zhao J; Falotico R
Expert Rev Clin Immunol; 2006 Jul; 2(4):649-58. PubMed ID: 20477620
[TBL] [Abstract][Full Text] [Related]
39. Pharmacotherapy of diseases mediated by 5-lipoxygenase pathway eicosanoids.
Rubin P; Mollison KW
Prostaglandins Other Lipid Mediat; 2007 May; 83(3):188-97. PubMed ID: 17481554
[TBL] [Abstract][Full Text] [Related]
40. Assessing 12(S)-lipoxygenase inhibitory activity using colorectal cancer cells overexpressing the enzyme.
Bednar W; Holzmann K; Marian B
Food Chem Toxicol; 2007 Mar; 45(3):508-14. PubMed ID: 17027136
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
